ivWatch's Revolutionary IV Monitoring Technology Now Accessible in UK NHS Supply Chain

ivWatch's Revolutionary IV Monitoring Technology Now Accessible in the UK NHS Supply Chain

ivWatch, recognized for its cutting-edge IV safety solutions, has recently achieved a significant milestone by having its continuous IV site monitoring system approved for inclusion in the NHS Supply Chain Innovation Products pathway. This marks an important step for hospitals across the UK, aiming to enhance patient safety and reduce complications associated with IV therapy.

The Rapid Inclusion Process

Typically, inclusion in national procurement pathways can take years, but ivWatch expedited this process, allowing NHS organizations to access vital technology quickly. The Innovation Products Pathway is designed to facilitate the adoption of technologies that address ongoing patient safety challenges. With the approval of ivWatch, NHS Trusts can now implement this sophisticated system to proactively tackle issues of IV infiltration and extravasation, which can cause unnecessary harm to patients.

The Impact of IV Infiltration and Extravasation

IV infiltration occurs when IV fluids leak into surrounding tissues rather than directly entering the bloodstream, while extravasation can lead to severe tissue damage. These complications can cause pain, treatment delays, and serious health risks for patients. The ivWatch system employs patented optical sensing technology and a predictive algorithm to continuously monitor the area surrounding an IV insertion site, enabling clinicians to detect potential issues at an early stage. Early intervention is crucial to mitigate risks and improve patient outcomes, ultimately reducing avoidable costs for healthcare facilities.

Views from NHS Leaders

Maya Aquino-Guerrero, Patient Safety Champion at NHS Supply Chain and a member of NIVAS, highlighted the transformative potential of this technology. "Technologies like ivWatch can markedly improve IV care by allowing for the timely detection of complications. This innovation supports clinicians in providing safe and high-quality patient care while optimizing the use of NHS resources."

Aquino-Guerrero also recently presented ivWatch’s advantages at the World Congress on Vascular Access, emphasizing its role in reducing the severity of IV-related injuries and relieving pressure on clinical staff.

Driving Change Through Clinical Leadership

Central to the successful integration of ivWatch within the NHS is Andrew Barton, a Nurse Consultant specializing in IV Therapy at Frimley Health NHS Foundation Trust. He has been instrumental in the clinical trial and implementation processes for ivWatch technology. In his research, the system demonstrated a superior ability to identify infiltration and extravasation events compared to traditional methods, confirming its efficacy in real-world clinical settings.

Barton noted the significant changes that ivWatch has brought to IV therapy practices: "We have seen a remarkable decrease in incidents of extravasation, translating to safer patient experiences. The prompt access to ivWatch through the NHS Supply Chain shows the importance of innovation in tackling longstanding challenges."

A Pathway Towards Broader Adoption

The inclusion of ivWatch in the Innovation Products portfolio means that NHS organizations, ranging from acute Trusts to specialized units, can acquire ivWatch technology through established procurement channels. This accessibility leads to immediate improvements in addressing IV safety issues across various medical pathways, including chemotherapy treatments, emergency care, and pediatric services.

ivWatch is committed to collaborating with NHS clinicians to continue education, generate evidence, and support the implementation process. This ensures that the healthcare teams involved can maximize benefits regarding patient safety and quality of care.

About ivWatch

Founded in 2010, ivWatch aims to revolutionize IV safety, addressing issues such as infiltration and extravasation that can result in severe patient consequences. With nearly 70 patents, ivWatch has developed a first-of-its-kind FDA-cleared device that continuously monitors IVs, significantly improving early detection of complications. For further information, visit ivWatch.

Conclusion

The integration of ivWatch's monitoring technology into the NHS Supply Chain represents a vital step towards enhancing patient safety protocols across UK hospitals. With strong clinical support and innovative solutions, the future of IV therapy practices looks promising for both healthcare professionals and patients.